In light of relatively limited tumor suppression on CT26 tumors even with a high dose (30 μg) of LPP-CT26 immunization (Fig. 4G), we investigated the potential synergistic effects of LPP-CT26 with an anti-PD1 (a-PD1) ICI (Fig. 8). Here, DDX53 is linked to neoplasm.